Ladenburg Thalmann Starts Aviragen Therapeutics (AVIR) at Buy

September 21, 2016 7:16 AM EDT
Get Alerts AVIR Hot Sheet
Price: $1.94 +2.11%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 19
Trade AVIR Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Ladenburg Thalmann initiated coverage on Aviragen Therapeutics (NASDAQ: AVIR) with a Buy rating and a price target of $2.50.

For an analyst ratings summary and ratings history on Aviragen Therapeutics click here. For more ratings news on Aviragen Therapeutics click here.

Shares of Aviragen Therapeutics closed at $1.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Ladenburg Thalmann Financial Services

Add Your Comment